REG - GSK PLC - Statement: Zantac (ranitidine) litigation

GSKAnnouncement

24/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240524:nRSX7523Pa&default-theme=true

RNS Number : 7523P  GSK PLC  24 May 2024

Issued: 23 May 2024, London UK

 

Statement: Zantac (ranitidine) litigation - Valadez and Williams cases

 

·  Jury in Valadez case in Illinois state court finds GSK not liable for
plaintiff's colorectal cancer

·  Verdict is consistent with scientific consensus that there is no
consistent or reliable evidence that ranitidine increases the risk of any
cancer

·   GSK will continue to vigorously defend itself against all other claims

·   Next Zantac trial (Williams) due to start in Illinois dismissed

 

 

GSK plc (LSE/NYSE: GSK) welcomes today's jury verdict in the Valadez case in
Illinois state court finding in GSK's favour in the first Zantac case to go to
trial. This outcome is consistent with the scientific consensus that there is
no consistent or reliable evidence that ranitidine increases the risk of any
cancer, supported by 16 epidemiological studies looking at human data
regarding the use of ranitidine. GSK will continue to vigorously defend itself
against all other claims.

 

Prior to this verdict, the court rejected the Plaintiff's ability to request
punitive damages.

 

Separately, the company welcomed the recent court ruling dismissing the next
Zantac trial (Williams) that was due to start on 23 May 2024. In the Williams
case, the Illinois state court dismissed the case before trial on the basis
that GSK was not the brand manufacturer of over-the-counter Zantac at the time
the Plaintiff allegedly used it and should not be liable for any subsequent
over-the-counter Zantac use.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Simon Moore        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q1 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRAJMTTMTBTTMI